JPH0376318B2 - - Google Patents

Info

Publication number
JPH0376318B2
JPH0376318B2 JP60156680A JP15668085A JPH0376318B2 JP H0376318 B2 JPH0376318 B2 JP H0376318B2 JP 60156680 A JP60156680 A JP 60156680A JP 15668085 A JP15668085 A JP 15668085A JP H0376318 B2 JPH0376318 B2 JP H0376318B2
Authority
JP
Japan
Prior art keywords
mmol
added
compound
benzimidazole
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60156680A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6216477A (ja
Inventor
Nobukatsu Sato
Haruo Kuryama
Masanobu Ago
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maruishi Pharmaceutical Co Ltd
Original Assignee
Maruishi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruishi Pharmaceutical Co Ltd filed Critical Maruishi Pharmaceutical Co Ltd
Priority to JP60156680A priority Critical patent/JPS6216477A/ja
Priority to US06/884,624 priority patent/US4714764A/en
Priority to EP86109650A priority patent/EP0209106B1/en
Priority to DE8686109650T priority patent/DE3666431D1/de
Priority to CA000513836A priority patent/CA1279647C/en
Publication of JPS6216477A publication Critical patent/JPS6216477A/ja
Publication of JPH0376318B2 publication Critical patent/JPH0376318B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP60156680A 1985-07-15 1985-07-15 抗ウイルス活性を有する２−（４−ピリジルアミノメチル）−ベンズイミダゾ−ル誘導体 Granted JPS6216477A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP60156680A JPS6216477A (ja) 1985-07-15 1985-07-15 抗ウイルス活性を有する２−（４−ピリジルアミノメチル）−ベンズイミダゾ−ル誘導体
US06/884,624 US4714764A (en) 1985-07-15 1986-07-11 2-(4-pyridylaminomethyl)-benzimidazole derivatives having antiviral activity
EP86109650A EP0209106B1 (en) 1985-07-15 1986-07-14 2-(4-pyridylaminomethyl)-benzimidazole derivatives and pharmaceutical compositions
DE8686109650T DE3666431D1 (en) 1985-07-15 1986-07-14 2-(4-pyridylaminomethyl)-benzimidazole derivatives and pharmaceutical compositions
CA000513836A CA1279647C (en) 1985-07-15 1986-07-15 2-(4-pyridylaminomethyl)-benzimidazole derivatives having antivirus activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60156680A JPS6216477A (ja) 1985-07-15 1985-07-15 抗ウイルス活性を有する２−（４−ピリジルアミノメチル）−ベンズイミダゾ−ル誘導体

Publications (2)

Publication Number Publication Date
JPS6216477A JPS6216477A (ja) 1987-01-24
JPH0376318B2 true JPH0376318B2 (enExample) 1991-12-05

Family

ID=15632974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60156680A Granted JPS6216477A (ja) 1985-07-15 1985-07-15 抗ウイルス活性を有する２−（４−ピリジルアミノメチル）−ベンズイミダゾ−ル誘導体

Country Status (5)

Country Link
US (1) US4714764A (enExample)
EP (1) EP0209106B1 (enExample)
JP (1) JPS6216477A (enExample)
CA (1) CA1279647C (enExample)
DE (1) DE3666431D1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1279648C (en) * 1986-07-11 1991-01-29 Haruo Kuriyama 2-(4-pyridylaminometyl)-benzimidazole derivatives having antiviral activity
DE3634066A1 (de) * 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US4977144A (en) * 1988-08-02 1990-12-11 Ciba-Geigy Corporation Imidazo[4,5-b]pyridine derivatives as cardiovascular agents
AU666078B2 (en) * 1993-07-02 1996-01-25 Elephant Chain Block Company Limited Manual chain block
US5586751A (en) * 1993-09-14 1996-12-24 Elephant Chain Block Company, Ltd. Manual chain block
US5672858A (en) 1994-06-30 1997-09-30 Symbol Technologies Inc. Apparatus and method for reading indicia using charge coupled device and scanning laser beam technology
US7638518B2 (en) * 2006-10-17 2009-12-29 Janssen Pharmaceutica Substituted pyrazole kinase inhibitors
CA2820078C (en) 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
JP5766820B2 (ja) 2011-02-09 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｉ３キナーゼ阻害剤としての複素環化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4506074A (en) * 1982-11-08 1985-03-19 Merck & Co., Inc. 2-[2-Pyridinyloxy(thio or amino)methyl]-1H-imidazoles and derivatives

Also Published As

Publication number Publication date
US4714764A (en) 1987-12-22
DE3666431D1 (en) 1989-11-23
CA1279647C (en) 1991-01-29
JPS6216477A (ja) 1987-01-24
EP0209106B1 (en) 1989-10-18
EP0209106A1 (en) 1987-01-21

Similar Documents

Publication Publication Date Title
NO139048B (no) Analogifremgangsmaate for fremstilling av nye analgetisk og/eller antiinflammatorisk virksomme (4h)-5,6-dihydro-(4,3-a)-s-triazolo-1,5-benzodiazepiner
JPS5823876B2 (ja) １−スルホニルベンゾイミダゾ−ル化合物
CN103588709B (zh) 一种依达拉奉的制备方法
CN111233870A (zh) 用于快速制备瑞德西韦药物中间体的方法
JP2016147807A (ja) ヒドロキサム酸誘導体またはその塩
CN111518104B (zh) 一种含硫脲嘧啶的1,2,4-三氮唑并[1,5-a]嘧啶类化合物及其制备方法和应用
JPH0376318B2 (enExample)
CN115260167B (zh) 一种3-四唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用
CA1076582A (en) Antiviral thiazolinyl or thiazinyl ketobenzimidazoles
CN103360398B (zh) 一种三唑并嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
JP2025138626A (ja) ３－トリアゾリルメチル－１，３，５－トリアジン－２，４－ジオン化合物、およびその調製方法と応用
JPH02138266A (ja) ６‐フェニル‐３‐（ピペラジニルアルキル）‐２，４（１ｈ，３ｈ）‐ピリミジンジオン誘導体
CN115304584B (zh) 3-硫甲基-(5’-芳基-1h-吡唑)-吲哚类化合物及其制备方法和用途
CN104402819B (zh) 一类双吡唑酰胺衍生物的制备及其在治理水稻黑条矮缩病中的应用
JPH0782268A (ja) ベンゾチアジアゾール誘導体の製法
CN114560862A (zh) 一种吡咯并[1,2-a]喹喔啉-4(5h)-酮及其衍生物的合成方法
CN111592505A (zh) 一种碘催化2-取代苯并硒唑类化合物的合成方法
CN101585819A (zh) 1,2,3-噻二唑巯乙酰胺类衍生物的制备方法
WO2022011948A1 (zh) 制备沃替西汀的方法
CN106008653A (zh) 甘草次酸酰腙类衍生物及其制备方法和用途
CN111848527A (zh) 一种4-氯-2-（2-氟-4-甲氧基苯基）-6-甲氧基喹唑啉及其合成方法
CN100500650C (zh) 一种腈类物质的化学合成方法
CN111606926B (zh) 一种苯并咪唑[1,3]氮硫杂卓类化合物的制备方法
CN103664804B (zh) 吡考他胺类似物、制备方法及其应用
CN113929635B (zh) 1,6-二苯基-1H-苯并[d][1,2,3]三唑类化合物及其制备方法与用途

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees